TP53 and acute myeloid leukemia: We show that M3814 can enhance the SoC AML treatment, daunorubicin (DNR) plus cytarabine (AraC), or their liposomal formulation, CPX-351, in p53 wild-type leukemia cells in vitro and in an in vivo PDX model of AML.